Verrica Pharmaceuticals Inc. Common Stock (VRCA) is a publicly traded Healthcare sector company. As of May 21, 2026, VRCA trades at $6.14 with a market cap of $100.84M and a P/E ratio of -5.37. VRCA moved +6.80% today. Year to date, VRCA is -32.13%; over the trailing twelve months it is -6.39%. Its 52-week range spans $3.28 to $17.49. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces VRCA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Verrica Q1 Revenue Jumps 60% to $6.7M, Net Loss Narrows: Verrica Pharmaceuticals’ Q1 2026 revenue rose 60% year-over-year to $6.7 million, driven by higher ZILXI net product sales. Operating expenses declined 12% to $11.9 million, narrowing net loss to $5.2 million from $6.8 million a year earlier.
| Metric | Value |
|---|---|
| Price | $6.14 |
| Market Cap | $100.84M |
| P/E Ratio | -5.37 |
| EPS | $-1.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.49 |
| 52-Week Low | $3.28 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $37.16M |
| Net Income | $-17.83M |
| Gross Margin | 0.00% |
2 analysts cover VRCA: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.